CD8A and neoplasm: It has been found that the major histocompatibility complex II (MHC II) UVM vaccine can activate tumor-specific CD8+T cells and CD4+T cells, thereby killing tumor cells but does not affect normal cells, suggesting that the high-risk group receiving the MHC II UVM vaccine may have better efficacy (77).